Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Online Videos | News | Weblinks | Pharmacy | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options: See related products available from our registered pharmacy AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Hypertension

Hypertension is a major risk factor for cardiovascular disease (CVD - cerebrovascular events and ischaemic heart disease) and is therefore one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. Recent Quality and outcomes framework (QOF) data suggest a prevalence of 11.3% in the UK population.
It is often symptomless, so screening is vital - before damage is done. Many surveys continue to show hypertension remains underdiagnosed, undertreated and poorly controlled in the UK.1

Defining hypertension

Blood pressure (BP) has a skewed normal distribution within the population and the currently accepted model assumes risk is continuously related to blood pressure.2,3,4

Optimal 120/80 mm/Hg5,6
Normal <130/<85 mm/Hg
High normal 130-139/85-89 mm/Hg
(labelled "pre-hypertension" in USA)

Hypertension

Mild hypertension Grade 1 140-159/90-99 mm/Hg
Moderate hypertension Grade 2 160-179/100-109 mm/Hg
Severe hypertension Grade 3 180/110 mm/Hg

Isolated systolic hypertension

Grade 1 140-159/<90 mm/Hg
Grade 2 160/<90 mm/Hg

When defining hypertension, we choose to select a value above which risk is significantly increased e.g. a total CVD risk 20% over 10 years,7 and the benefit of treatment is clear-cut. A figure of 160/100 mmHg is usually quoted.

Associated risk

Although there are geographical differences in blood pressure (the absolute risk at the same level of blood pressure varies substantially), the relative increase in long-term mortality due to CVD for a given increase in blood pressure is similar.4
However, hypertension is only one of several cardiovascular risk factors and assessment of overall risk is vital, as it will affect the level of blood pressure one selects to treat; a cut-off of 140/90 mmHg should be used for those with an absolute risk of 1.5% per annum: see Management of Hypertension.

Other considerations
  • Malignant hypertension: This is a syndrome characterised by severe hypertension (e.g. systolic >200, diastolic>130 mmHg) accompanied by encephalopathy or nephropathy, or by papilloedema and/or angiopathic haemolytic anaemia. Accelerated hypertension has been used to describe acutely elevated blood pressure with haemorrhages or exudates on fundoscopy. Both need urgent treatment.
  • Systolic or diastolic pressure: For many years diastolic pressure was considered to be more important than systolic pressure. However, evidence from the Framingham study8 and MrFIT study9 indicates that systolic pressure is the most important determinant of cardiovascular risk.
  • Hypertension in the elderly: Although age-related rise in systolic pressure can be considered part of the 'normal' ageing process, isolated systolic hypertension (ISH) in the elderly should not be ignored; the benefits of treatment are far greater than treating moderate hypertension in middle-aged patients.10,11
Measuring blood pressure5,6

All adults should have their BP measured, at least every 5 years up to the age 80. Those with high normal values (130-139/85-89 mmHg) should be checked annually.

  • Use a correctly calibrated and maintained machine (manual or automatic).
  • Seated BP is adequate except in elderly or diabetic patients who may have orthostatic hypotension (standing BP needed as well - after at least two minutes standing).5
  • Remove tight clothing and support the arm with hand relaxed and cuff (of appropriate size) at heart level.
  • Initially measure BP in both arms and subsequently use the arm with higher values for all measurements - in some patients the difference may be >10 mmHg.

Use automated machine or the following manual method:

  • Inflate cuff whilst palpating the brachial artery, until the pulse disappears. This provides an estimate of systolic pressure.
  • Inflate the cuff until 30 mmHg above systolic pressure, then place stethoscope over the brachial artery. Deflate the cuff at 2 mmHg per second.
  • Systolic pressure: the appearance of sustained repetitive tapping sounds (Korotkoff I). Diastolic pressure: usually the disappearance of sounds (Korotkoff V). However, in some individuals (e.g. pregnant women) sounds are present until the zero-point. In this case the muffling of sounds,(Korotkoff IV), should be used.
  • Record to the nearest 2 mmHg.
  • In the assessment of uncomplicated borderline cases, the average of two readings on each monthly visit for 4-6 months should be used when deciding to whether to treat.

Ambulatory blood pressure monitoring (ABPM)

Although outcome trials have been based on clinic or surgery BP measurement, ABPM may provide more information in equivocal treatment decisions.
There is also an increasing body of evidence that they may be a better predictor of CVD.12It is particularly indicated if:

  • BP shows unusual variability
  • BP is resistant to multiple-therapy
  • There is a possibility of either hypotension or "white coat" hypertension.
  • It is helpful in the diagnosis and assessment of both hypertension in pregnancy and nocturnal hypertension (or in evaluating the efficacy of BP treatment over 24 hours).

Use validated machines (wrist monitors not recommended).4
Measurements need adjusting upwards to compare with clinic readings by approximately 10/5 mmHg and optimum ABPM targets should be <130/80 (<130/75 in diabetics), although there is little evidence for true equivalence.5 Patients can take their own BPs satisfactorily,13 but may be subject to recording bias as much as GPs.

Aetiology

Essential hypertension (primary, cause unknown) accounts for the majority of cases.
Secondary hypertension is commonly caused by renal disease or pregnancy.

Renal disease

~75% are from intrinsic renal disease: glomerulonephritis, polyarteritis nodosa, systemic sclerosis, chronic pyelonephritis, or polycystic kidneys.
~25% are due to renovascular disease most frequently atheromatous (elderly cigarette smokers, e.g. with peripheral vascular disease) or fibromuscular dysplasia (more common in younger females).

Others

Coarctation, pre-eclampsia/pregnancy, drugs

Presentation

Usually asymptomatic, except malignant hypertension.

Initial evaluation of hypertensive patient

All patients need a full history and physical examination.
Look hard for a cause in the young, severe hypertensive; be more restrained in the older patient, as diagnostic yield and treatment benefits are less.
Start by talking to the patient:

  • Take a full drug history (NSAIDs, oral contraceptives, steroids, liquorice, sympathomimetics ie. cold cures).
  • Is he or she aware of the hypertension? Episodic feelings 'as if about to die' or headaches, or paroxysmal sweats or palpitations, suggests phaeochromocytoma
  • Consider renal causes: Is there a present, past or family history of renal disease? Are the kidneys palpable? Is there an abdominal or loin bruit (renovascular disease) or delayed or weak femoral pulses (coarctation).
  • Does the patient look cushingoid or might he have Conn's syndrome (tetany, weak muscles, polyuria, hypokalaemia)?
  • Consider contributory factors: obesity, excess alcohol, salt intake and lack of exercise, environmental stress, and cardiovascular risk factors (smoking, diabetes, cholesterol and family history) ready for your management plan (use Primary CVD Risk Calculator if appropriate).7

Assess degree of end organ damage or complications of hypertension; previous stroke, TIA, dementia or known LVH/LV strain, IHD, peripheral vascular disease, renal impairment? Perform ophthalmoscopy; dilate with 1% tropicamide if poor view.

Investigations

Routine investigation should be limited to:

  • Urine dipstick test for protein and blood
  • Serum creatinine and electrolytes
  • Fasting blood glucose
  • Fasting serum total and HDL cholesterol
  • ECG
  • Echocardiography - useful in young patients who commonly have ECGs with voltage criteria of LVH, without T wave abnormalities
  • Specific (if a secondary cause suspected):
    • Plasma calcium
    • CXR
    • Renal ultrasound
    • IVU
    • Renal arteriography
    • 24 hour urinary VMA x 3
    • Urinary free cortisol

Referral to a specialist may be appropriate for some of these tests.

Indications for specialist referral4
  • Urgent treatment needed: malignant hypertension, severe hypertension (>220/>120 mmHg) or impending complications (e.g. transient ischaemic attack, left ventricular failure).
  • Possible underlying cause: low K , Na elevated (possible Conn's); elevated creatinine, proteinuria or haematuria; sudden onset or rapidly worsening or resistant hypertension (i.e. needs >3 drugs); Young Age: patient aged <20, or <30 years needing treatment.
  • Therapeutic problems: multiple drug intolerance or contraindications, persistent non-compliance or treatment refusal (the reluctant hypertensive).
  • Special situations: hypertension in pregnancy,14 unusual BP variability, "white coat hypertension".
Management

For a full discussion on CVD risk assessment, treatment thresholds and their modification dependent on target organ damage and concurrent diseases see related article Management of Hypertension.


Document references
  1. Wolf-Maier K, Cooper RS, Kramer H, et al; Hypertension treatment and control in five European countries, Canada, and the United States.; Hypertension. 2004 Jan;43(1):10-7. Epub 2003 Nov 24. [abstract]
  2. Alderman MH; Measures and meaning of blood pressure. Lancet. 2000 Jan 15;355(9199):159.
  3. Port S, Demer L, Jennrich R, et al; Systolic blood pressure and mortality. Lancet. 2000 Jan 15;355(9199):175-80. [abstract]
  4. Ezzati M, Lopez AD, Rodgers A, et al; Selected major risk factors and global and regional burden of disease. Lancet. 2002 Nov 2;360(9343):1347-60. [abstract]
  5. Guidelines for management of hypertension, British Hypertension Society (2004)
  6. No authors listed; 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.; J Hypertens. 2003 Jun;21(6):1011-53.
  7. No authors listed, JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 Dec;91 Suppl 5:v1-52.
  8. Sytkowski PA, Kannel WB, D'Agostino RB; Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990 Jun 7;322(23):1635-41. [abstract]
  9. Kannel WB, Neaton JD, Wentworth D, et al; Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J. 1986 Oct;112(4):825-36. [abstract]
  10. Lewington S, Clarke R, Qizilbash N, et al; Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. [abstract]
  11. Effectiveness matters. Drug Treatment of Essential Hypertension in Older people; Vol 4 issue 2; October 1999
  12. Clement DL, De Buyzere ML, De Bacquer DA, et al; Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003 Jun 12;348(24):2407-15. [abstract]
  13. Nordmann A, Frach B, Walker T, et al; Reliability of patients measuring blood pressure at home: prospective observational study. BMJ. 1999 Oct 30;319(7218):1172.
  14. Hypertension in pregnancy, Clinical Knowledge Summaries (2006)

Internet and further reading Acknowledgements EMIS is grateful to Dr Hayley Willacy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 2289
Document Version: 21
DocRef: bgp567
Last Updated: 29 Apr 2008
Review Date: 29 Apr 2010






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page